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Received April 26, 2013; accepted November 27, 2013AbstractBackground: Distinguishing the rates of Helicobacter pylori infection in chronic kidney disease (CKD) and end-stage renal disease (ESRD)
patients with peptic ulcer disease (PUD) from that in PUD patients without CKD is critical.
Methods: We first stratified the original 1 million study population according to CKD or ESRD. We retrospectively investigated the incidence of
H. pylori infection in PUD patients with or without CKD or ESRD between 2000 and 2008 in a nationwide, population-based cohort using data
from the Taiwan National Health Insurance Research Database. The comparison cohort consisted of PUD patients without CKD. A logistic
regression model was used to calculate the odds ratios (ORs) and 95% confidence intervals, to determine whether the occurrence of H. pylori
infection in CKD or ESRD patients with PUD differed from that of PUD patients without CKD.
Results: Among the CKD patients, 261 patients had H. pylori-positive and 185 H. pylori-negative peptic ulcers. Among the ESRD patients, 81
had H. pylori-positive and 63 H. pylori-negative peptic ulcers. Among the non-CKD control patients, 1658 patients had H. pylori-positive and
702 H. pylori-negative peptic ulcers. Our results revealed a lower H. pylori infection rate in CKD (OR ¼ 0.64, p < 0.001) and ESRD
(OR ¼ 0.54, p ¼ 0.001) patients with PUD than in PUD patients without CKD.
Conclusion: The H. pylori infection rate is lower in PUD patients with CKD and ESRD than in those without CKD.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Uremic patients exhibit a higher incidence of peptic ulcer
disease (PUD) than nonuremic patients.1e3 Helicobacter py-
lori plays a central role in the development of chronic gastritis,
gastric ulcers, duodenal ulcers, and gastric cancer.4e6 TheConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2014.04.004
1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Assdifference in H. pylori infection rates between uremic and
nonuremic patients with PUD warrants further investigation.
Increased gastrin level,7 gastric acid hypersecretion,8 and
gastric acid hyposecretion9 are relevant to the pathology of
gastrointestinal lesions in uremic patients. Interactions among
hosts, pathogens, and environmental factors are crucial to H.
pylori colonization.10,11 Studies on H. pylori infection in
uremic patients have reported infection rates to vary from 27%
to 73.0%.1,3,12e18 The variation might have been caused by
small sample size, nonuniform duration of dialysis, varying
methodologies, and different enrollment criteria.
Distinguishing the rates of H. pylori infection in chronic
kidney disease (CKD) and end-stage renal disease (ESRD)ociation. All rights reserved.
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critical. Neither a large clinical trial nor a nationally repre-
sentative observational study has been conducted to address
this health care concern. Therefore, we analyzed H. pylori
infection in patients with PUD, and grouped the participants as
CKD, ESRD, and non-CKD patients. The objective of our
study was to determine whether the risk of H. pylori infection
among CKD and ESRD patients with PUD differs from that of
non-CKD patients with PUD.
2. Methods2.1. Ethics statementIn our study, all data that could be used to identify patients
were obtained from the National Health Insurance (NHI) files.
To ensure confidentiality of the data presented in our study,
which was approved by the National Health Research Institute
(NHRI), Taiwan, we adhered to the regulations of the Bureau
of National Health Insurance, Taiwan. The Institutional Re-
view Board (IRB) of Taipei City Hospital, Taipei, Taiwan
approved this study (IRB Number: TCHIRB-1020424-E).2.2. Study populationOur nationwide, population-based cohort consisted of pa-
tients selected from the National Health Insurance Database
(NHID) from claims records collected between January 1,
2000 and December 31, 2008. The NHID, which is managed
by the NHRI, contains health care data for approximately 23
million people, who constitute 99% of the residents of
Taiwan. The National Health Insurance Research Database
(NHIRD) is also managed by the NHRI, is updated annually,
and consists of comprehensive data for a randomly selected
sample of 1 million NHI beneficiaries, representing approxi-
mately 5% of all enrollees. The NHIRD contains compre-
hensive patient data, including demographic data, dates of
clinical visits, diagnostic codes, and the details of medical
prescriptions. The diagnoses used in the NHIRD are coded
according to the diagnostic criteria of the International Clas-
sifications of Diseases, Revision 9, Clinical Modification
(ICD-9-CM).2.3. Study participantsWe conducted a retrospective cohort study based on
ambulatory care and inpatient discharge records in the NHIRD
recorded between 2000 and 2008. We first stratified the orig-
inal 1 million study population according to CKD or ESRD,
and then analyzed the prevalence of H. pylori infection among
the groups. We used ICD-9-CM codes (531.xx, 532.xx, or
533.xx) after the endoscopic examination to identify peptic
ulcer patients. All patients with peptic ulcers that were
endoscopically confirmed and clinically tested for the pres-
ence of H. pylori, based on the rapid urease test or hematox-
ylin and eosin histological staining, were considered for
inclusion in our PUD cohort.The PUD patients who were endoscopically diagnosed with
peptic ulcers between January 1, 1997 and December 31, 1999
were identified as those having a history of peptic ulcer. Patients
who had undergone gastrectomy or vagotomy, received a
diagnosis of gastric cancer or ZollingereEllison syndrome be-
tween 1997 and 2008, and patients who had undergoneH. pylori
eradication therapy between 1997 and 1999 were excluded.
According to the reimbursement policy of the NHI, patients
with a confirmed diagnosis of H. pylori-positive peptic ulcers
are reimbursed for 7e14 days of H. pylori eradication therapy.
In Taiwan, H. pylori infection is treated by performing a triple
or quadruple therapy, consisting of proton pump inhibitors
(PPIs) or histamine receptor-2 blockers (H2 blockers), clari-
thromycin or tetracycline, and amoxicillin or metronidazole
with or without bismuth. The PPIs used by the patients in our
cohort included lansoprazole, esomeprazole, omeprazole,
pantoprazole, and rabeprazole, and the H2 blockers used
included cimetidine, famotidine, nizatidine, ranitidine, and
roxatidine.19 Fig. 1 shows a flow chart depicting participant
selection in our study.2.4. H. pylori-associated peptic ulcersPhysicians are more likely to treat and test patients with
PUDs according to clinical practice guidelines.20 Therefore,
patients diagnosed with PUD with H. pylori infection were
defined as those who received 7e14 days of triple or
quadruple therapy during the same outpatient treatment period
or during the same hospitalization period. Patients without H.
pylori infection were defined as those who were prescribed
PPIs or H2 blockers for a minimum of 3 consecutive months
after undergoing gastroscopy and H. pylori diagnostic tests,
but did not receive the other components of H. pylori eradi-
cation therapy during PPI or H2 blocker treatment. We also
excluded patients receiving PPIs, H2 blockers, clarithromycin,
tetracycline, amoxicillin, metronidazole, bismuth, levo-
floxacin, and refabutin 4 weeks prior to H. pylori testing from
January 1, 2000 to December 31, 2008.2.5. Definition of CKD and ESRDIn Taiwan, ESRD patients requiring dialysis can apply to
receive a catastrophic illness card. Cardholders are exempt from
the cost sharing required by the NHI program. ESRD patients
were defined as the patients who had received a catastrophic
illness card and claimed for hemodialysis or peritoneal dialysis
for at least 3 months (ICD-9-CM 585). CKD patients were
defined as the non-ESRD patients whowere hospitalized at least
once or presented for three or more outpatient visits, in which
one or more of the following ICD-9-CM diagnostic codes were
used: 585-589, 250.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3,
440.1, 442.1, 447.3, 572.4, 642.1x, 646.2x, and 794.4.2.6. Definition of the control groupTo be defined as a non-CKD patient (control group), a person
could not have the following ICD-9-CM codes in his or her
I 
2000–2008 
Initial number of patients from NHIRD, 
excluding those with questionable or 
inadequate basic data (N = 965,845)  Exclusion criteria:  1. Age < 20 years  
2. Patients with previous gastrectomy, vagotomy, 
gastric cancer, or Zollinger-Ellison syndrome 
before peptic ulcer diagnosis (N = 262,142) 
Participants available for analysis since 
(N = 703,703) 
CKD patients 
(N = 23,506) 
ESRD patients 
(N = 4359) 
Control 
(N = 675,838) 
CKD patients with 
endoscopically confirmed 
peptic ulcer (rate) 
N = 1195 (5.08%) 
ESRD patients with 
endoscopically confirmed 
peptic ulcer (rate) 
N = 229 (5.25%) 
Non-CKD patients with 
endoscopically confirmed 
peptic ulcer (rate) 
N = 16,735 (2.48%) 
Exclusion criteria:  
1. Received H. pylori eradication therapy 
during 1997 to 1999 
2. Patients using proton pump inhibitors (PPIs), 
histamine receptor-2 blockers (H2 blockers), 
clarithromycin, tetracycline, amoxicillin, 
metronidazole, bismuth, levofloxacin, or 
rifabutin during the 4 weeks preceding H. 
pylori testing 
 (N = 7399)  
Four control patients were selected to match 
each patient diagnosed with CKD or ESRD 
based on age (N = 2360) 
Patients with endoscopically 
confirmed peptic ulcer and 
concurrent confirmation of H. pylori 
status.  
CKD patients (N = 446) 
ESRD patients (N = 144) 
Fig. 1. Flowchart depicting the selection of participants.
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250.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3, 440.1, 442.1,
447.3, 572.4, 642.1x, 646.2x, and 794.4. Four control patients
werematched to eachCKDorESRDpatient based on sex and age
group (20e49 years and 50 years). The participants were
categorized intoCKD, ESRD, and control groups, based onwhen
the ulcer eventswere identifiedusing ICD-9-CMdiagnosis codes.2.7. Definition of peptic ulcer historyAll CKD, ESRD, and non-CKD patients endoscopically
diagnosed to have peptic ulcers during 1997e1999, based on
ambulatory care and inpatient discharge records, were defined
as those having a peptic ulcer history. Peptic ulcers were
classified as gastric ulcers (ICD-9-CM 531.xx), duodenal ul-
cers (ICD-9-CM 532.xx), and nonspecific peptic ulcers (ICD-
9-CM 533.xx) after endoscopic examination claim.2.8. ComorbiditiesComorbidities were defined based on diagnostic codes
identified in at least one inpatient discharge record or three or
more ambulatory care claims. Comorbidities examined in our
study included the following conditions: diabetes mellitus,
ICD-9-CM 250; hypertension, ICD-9-CM 401-405; congestive
heart failure, ICD-9-CM 428; coronary artery disease, ICD-9-
CM 410-414; cerebral vascular disease, ICD-9-CM 430-438;
and liver cirrhosis, ICD-9-CM 571.2, 571.5, and 571.6.2.9. Medication usePatients who used aspirin, nonsteroidal anti-inflammatory
drugs (NSAIDs), cyclooxygenase-2-specific inhibitors, ste-
roids, selective serotonin-reuptake inhibitors, clopidogrel,
ticlopidine, or warfarin within 28 days prior to H. pylori
Table 1
Demographic and clinical characteristics of patients with peptic ulcer disease stratified according to CKD and ESRD status.
Variables Controlb CKDb ESRDb p
n ¼ 2360 % n ¼ 446 % n ¼ 144 %
Age (y) 0.102
20e49 276 11.69 45 10.09 24 16.67
50 2084 88.31 401 89.91 120 83.33
Sex 0.093
Male 1380 58.47 174 39.01 71 49.31
Female 980 41.53 272 60.99 73 50.69
Peptic ulcer history 169 7.16 29 6.50 5 3.47 0.223
Medication
Aspirin 161 6.82 65 14.57 15 10.42 <0.001
NSAIDs 60 2.54 18 4.04 2 1.39 0.124
COX-2 inhibitors 87 3.69 19 4.26 7 4.86 0.680
Steroid 22 0.93 13 2.91 4 2.78 0.001
SSRIs 21 0.89 7 1.57 4 2.78 0.050
Other medicationsa 35 1.48 15 3.36 3 2.08 0.023
Comorbidities
DM 379 16.06 229 51.35 65 45.14 <0.001
Hypertension 1090 46.19 316 70.85 104 72.22 <0.001
CHF 114 4.83 53 11.88 22 15.28 <0.001
CAD 512 21.69 173 38.79 53 36.81 <0.001
CVD 325 13.77 116 26.01 20 13.89 <0.001
Liver cirrhosis 70 2.97 16 3.59 5 3.47 0.756
H. pylori status <0.001
H. pylori () 702 29.75 185 41.48 63 43.75
H. pylori (þ) 1658 70.25 261 58.52 81 56.25
CAD ¼ cardiovascular disease; CHF ¼ congestive heart failure; CKD ¼ chronic kidney disease; COX-2 inhibitors ¼ cyclooxygenase-2-specific inhibitors;
CVD ¼ cerebral vascular disease; DM ¼ diabetes mellitus; ESRD ¼ end-stage renal disease; H. pylori (þ) ¼ Helicobacter pylori infection; H. pylori () ¼ no H.
pylori infection; n ¼ number of patients; NSAIDs ¼ nonsteroidal anti-inflammatory drugs; SSRIs ¼ selective serotonin-reuptake inhibitors.
a Other medications were clopidogrel, ticlopidine, or warfarin.
b The raw ulcer rates were 2.48% in the control group, 5.08% in the CKD group, and 5.25% in the ESRD group.
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aspirin users, NSAID users, cyclooxygenase-2-specific in-
hibitors users, steroid users, selective serotonin-reuptake in-
hibitor users, clopidogrel users, ticlopidine users, or warfarin
users.2.10. Statistical analysisThe number and percentage of patients were calculated for
the categorical variables, including age group, sex, medication
use, peptic ulcer history, and comorbidities. The differences
between the CKD, ESRD, and non-CKD study groups were
compared using a c2 test. A logistic regression model was
used to calculate the odds ratios (ORs) and the 95% confi-
dence intervals (CIs) for the occurrence of H. pylori infection
to determine whether CKD or ESRD was an independent
factor in H. pylori infection in PUD patients. Risk factors with
p < 0.1 in univariate logistic analysis were entered into the
multivariate analysis. Age, sex, peptic ulcer history, medica-
tions, and comorbidities were included as variables in the
model. All statistical analyses were performed using SAS for
Windows, version 9.2 (SAS Institute, Cary, NC, USA).
3. Results
Among the CKD patients, 261 had H. pylori-positive and
185 H. pylori-negative peptic ulcers. Among the ESRDpatients, 81 had H. pylori-positive and 63 had H. pylori-
negative peptic ulcers. Among the non-CKD control patients,
1658 had H. pylori-positive and 702 had H. pylori-negative
peptic ulcers. A lower H. pylori infection rate was observed
among the CKD (58.52%) and ESRD (56.25%) patients with
PUD, compared with the non-CKD patients with PUD
(70.35%). Table 1 lists other demographic data, including age,
sex, peptic ulcer history, medication use, and comorbidities.
Multivariate logistic regression analysis showed that CKD
(OR ¼ 0.64, p < 0.001) and ESRD (OR ¼ 0.54, p ¼ 0.001)
were associated with a lower incidence of H. pylori infection
in PUD patients, compared with that in PUD patients without
CKD (Table 2). A peptic ulcer history (OR ¼ 0.53, p < 0.001),
NSAID use (OR ¼ 0.62, p ¼ 0.043), and liver cirrhosis
(OR ¼ 0.45, p < 0.001) were also associated with a lower
incidence of H. pylori infection in PUD patients, compared
with those in PUD patients without the respective comorbidity.
The incidence of H. pylori infection is higher in PUD patients
aged 20e49 years (OR ¼ 2.28, p < 0.001) than in older
patients.
4. Discussion
Our data showed a lower H. pylori infection rate in CKD
and ESRD patients with PUD than in PUD patients without
CKD. High serum urea nitrogen contributes to hypoacid
secretion, and high gastric pH has been proposed as the cause
Table 2
Uni- and multivariate logistic regression results for predicting Helicobacter
pylori infection in patients with peptic ulcer disease.
Variables Univariate Multivariate*
OR 95% CI p OR 95% CI p
Age (y)
20e49 vs.
50
2.52 1.88e3.37 <0.001 2.28 1.68e3.10 <0.001
Sex
Male vs.
female
1.04 0.89e1.21 0.659 d d d
Kidney disease
CKD vs.
control
0.60 0.49e0.74 <0.001 0.64 0.51e0.81 <0.001
ESRD vs.
control
0.54 0.39e0.77 <0.001 0.54 0.38e0.77 <0.001
Peptic ulcer history
Yes vs. no 0.53 0.39e0.70 <0.001 0.53 0.40e0.72 <0.001
Aspirin
User vs.
nonuser
0.99 0.75e1.32 0.955 d d d
NSAIDs
User vs.
nonuser
0.54 0.35e0.85 0.007 0.62 0.40e0.99 0.043
COX-2 inhibitors
User vs.
nonuser
0.77 0.52e1.13 0.176 d d d
Steroid
User vs.
nonuser
0.45 0.24e0.84 0.012 0.58 0.30e1.11 0.101
SSRIs
User vs.
nonuser
0.91 0.44e1.89 0.792 d d d
Other medicationsa
User vs.
nonuser
0.53 0.31e0.91 0.021 0.61 0.35e1.07 0.086
DM
Yes vs. no 0.75 0.63e0.90 0.002 1.02 0.83e1.24 0.876
Hypertension
Yes vs. no 0.68 0.59e0.80 <0.001 0.89 0.75e1.06 0.198
CHF
Yes vs. no 0.64 0.48e0.87 0.004 0.88 0.64e1.20 0.411
CAD
Yes vs. no 0.69 0.58e0.83 <0.001 0.89 0.74e1.08 0.256
CVD
Yes vs. no 0.88 0.71e1.08 0.211 d d d
Liver cirrhosis
Yes vs. no 0.45 0.30e0.69 <0.001 0.45 0.29e0.69 <0.001
Variables where *p < 0.1 were put into multivariate analysis.
CAD ¼ cardiovascular disease; CHF ¼ congestive heart failure;
CI ¼ confidence interval; CKD ¼ chronic kidney disease; COX-2
inhibitors ¼ cyclooxygenase-2-specific inhibitors; CVD ¼ cerebral vascular
disease; DM ¼ diabetes mellitus; ESRD ¼ end-stage renal disease;
NSAIDs ¼ nonsteroidal anti-inflammatory drugs; OR ¼ odds ratio;
SSRIs ¼ selective serotonin-reuptake inhibitors.
a Other medications were clopidogrel, ticlopidine, or warfarin.
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et al18 reported an H. pylori infection rate of 38.3% in ESRD
patients receiving dialysis for 4 years, suggesting that longer
durations of dialysis reduce the risk of H. pylori infection.
Prostaglandin is a crucial factor for protecting the gastric
mucosa against injury, and uremic patients often experience a
reduction in mucosal prostaglandin.1 Therefore, a reduction inmucosal prostaglandin and hypergastrinemia7 may contribute
to the development of peptic ulcers in the absence of H. pylori
in CKD patients.
Findings of previous studies on the prevalence of H. pylori
infection in uremic patients vary. Such variation may be
attributed to the use of different methodologies and enrollment
criteria. Our findings differ from those of Luzza et al,15 who
showed a higher H. pylori infection rate in uremic patients.
However, they used the method of measuring serum anti-H.
pylori immunoglobulin G antibody levels to confirm H. pylori
infection, which have a lower specificity than those of the
rapid urease and histological methods that were used in our
study. The 2007 Maastricht III Consensus Report on diagnosis
and treatment of H. pylori infection does not recommend the
serological determination of H. pylori infection in routine
clinical practice.20 In addition, this study enrolled uremia
patients, and analyzed dyspepsia and dyspeptic symptoms
based on the results of a questionnaire, without confirming
peptic ulcer endoscopically. However, our study enrolled only
patients with peptic ulcers confirmed by conducting endo-
scopic examination. Thus, the differences in the methodolo-
gies and enrollment criteria may explain the discrepancies
between our findings and those of Luzza et al.15
Our nationwide, population-based observational study
revealed H. pylori infection rates of 58.52% and 56.25% in
CKD and ESRD patients with PUD, respectively, whereas
70.35% of the PUD patients without CKD were H. pylori-
positive. Previous studies1,18 have reported lower H. pylori
infection rates, ranging from 22.6% to 42.9% (in Asian
countries) in uremic patients with gastrointestinal mucosal
lesions and peptic ulcers. These previous studies have used
rapid urease tests or hematoxylin and eosin staining to di-
agnose H. pylori infection. Uremic patients are at a high risk
of damage to the gastric mucosa because of fluctuations in the
gastric blood supply17 and increased inflammation. Thus,
uremic patients are likely to be at an increased risk for peptic
ulcers and gastric erosions in the absence of H. pylori. How-
ever, the H. pylori infection rate varies from region to region.
Therefore, caution must be taken in extrapolating our results to
Western developed countries, which have lower H. pylori
prevalence rates.
In our analysis, patients with a history of peptic ulcer had
significantly lower H. pylori infection rates, for which we
propose two possible explanations. First, physicians are more
likely to treat and test patients with PUDs according to clinical
practice guidelines.20 Therefore, non-CKD patients with a
peptic ulcer history are likely to have received H. pylori
eradication therapy prior to 1997. A recent multicenter study
in Taiwan21 reported a PPI-based H. pylori eradication rate of
approximately 87.1%, and Cameron et al22 reported an annual
H. pylori reinfection rate of 0.4%, suggesting that the rate of
H. pylori infection is lower in patients with recurrent peptic
ulcers. Second, CKD and ESRD patients exhibit a higher
incidence of PUD than non-CKD patients,1,2 and are at an
increased risk of developing ulcerative conditions through
pathogenic mechanisms other than H. pylori infection. The
presence of comorbidities, such as malignancy, diabetes
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vascular disease, and liver cirrhosis, are independent pre-
dictors for non-H. pylori peptic ulcers.23e25 Therefore, factors
other than H. pylori infection play essential roles in the
development of peptic ulcers in patients with ESRD or liver
cirrhosis,1,25 which is consistent with our findings (OR ¼ 0.45,
p < 0.001 for liver cirrhosis).
Several limitations to our findings should be noted. First,
pathological classification is crucial for distinguishing be-
tween inflammation (gastritis) and H. pylori infection. Patients
with a confirmed diagnosis of atrophic gastritis with concur-
rent H. pylori infection are not reimbursed by the NHI for H.
pylori eradication therapy. Therefore, caution should be
exercised when extending our findings to other patient pop-
ulations, such as nonulcer dyspepsia patients, patients with
atrophic gastritis, or the general population. Second, because
certain laboratory data, such as serum creatinine and urine
creatinine levels, were not recorded in the NHIRD, we used
ICD-9-CM code 585 and the catastrophic illness card-holder
status to identify ESRD patients, rather than basing the iden-
tification on the glomerular filtration rate. Third, the NHIRD
does not contain data regarding patients’ antibiotic allergy
status. Therefore, because patients with relevant antibiotic
allergies do not receive H. pylori eradication therapy, they may
have been misclassified as H. pylori-negative patients.
In conclusion, our data showed that the H. pylori infection
rate among CKD and ESRD patients with PUD is lower than
that in PUD patients without CKD. Whether H. pylori eradi-
cation therapy can reduce the recurrence of peptic ulcers in
CKD and ESRD patients in a manner similar to that achieved
in the general population26 warrants further study.
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